摘要
目的探讨米非司酮联合宫瘤消对子宫肌瘤患者细胞因子和性激素水平的影响。方法选取2014年1月至2015年1月在胶州市现代医院接受治疗的子宫肌瘤患者100例。按照随机数字表法将其分为对照组和观察组,各50例。对照组患者采用单纯米非司酮进行治疗,口服剂量为25 mg/d,每日1次;观察组患者采用米非司酮联合宫瘤消胶囊进行治疗,宫瘤消胶囊6粒/次,每日3次,米非司酮的口服剂量同对照组。评价并比较两组患者治疗后的临床疗效,比较两组患者治疗前后血中细胞因子和性激素的水平情况及不良反应发生情况。结果治疗后两组患者白细胞介素2(IL-2)水平较治疗前显著升高(P<0.05),肿瘤坏死因子α(TNF-α)水平较治疗前显著降低(P<0.05);观察组患者治疗后的IL-2水平显著高于对照组[(21.1±4.2)μg/L比(15.2±4.0)μg/L],TNF-α水平显著低于对照组[(22±5)pg/L比(31±9)pg/L],差异有统计学意义(P<0.05)。治疗后两组患者的雌二醇、孕激素、促卵泡素(FSH)、促黄体素(LH)水平均较治疗前显著降低(P<0.05),且观察组患者孕激素、雌二醇、FSH、LH低于对照组[(1.08±0.32)nmol/L比(1.37±0.44)nmol/L,(42.68±2.94)pmol/L比(56.44±3.16)pmol/L,(12.24±3.56)U/L比(15.43±3.86)U/L,(12.57±2.87)U/L比(15.48±3.54)U/L],差异有统计学意义(P<0.05)。观察组总有效率显著高于对照组[68.0%(34/50)比92.0%(46/50),P<0.05],不良反应总发生率显著低于对照组[46.0%(23/50)比20.0%(10/50)],差异有统计学意义(P<0.05)。结论米非司酮联合宫瘤消胶囊能有效改善子宫肌瘤患者细胞因子和性激素水平,提高治疗效果并且降低不良反应,值得在临床广泛推广。
Objective To investigate the effect of mifepristone combined with uterine tumor eliminator on cytokine and sex hormones level in patients with uterine fibroids. Methods Total of 100 patients with uterine fibroids treated in Modern hospital of Jiaozhou City from Jan. 2014 to Jan. 2015 were included In the study, and divided into a contral group and an observation group according to the random number table method, 50 cases in each group. The control group was treated with mifepristonc,25 mg/d,once per day;the observa- tion group was treated with mifepristone（ same as the control group） combined with uterine tumor eliminator capsule（6 capsules/time, three times per day）. The cllnieal efficacy of the two groups after treatment were evaluated and compared,and the blood cytokines and sex hormone levels of the two groups before and after treatment and the adverse reactions were compared. Results The level of interleukin （IL）-2 in the two groups after treatment were significantly higher than before treatment （ P 〈 0. 05 ） , tumor necrosis factor （TNF）-ct level was significandy lower than before treatment（ P 〈 0.05 ） ;and the IL-2 observation group was significantly lower than the control group[ （21.1 ±4. 2） μg/L vs （ 15.2±4. 0） μg/L], the TNF-α level of the observation group was significantly higher than the control group[ （22 ±5） pg/L vs （31±9） pg/L], the difference was significantly significant （P 〈 0.05 ）. After treatment, estradiol and progesterone, follicle stimulating prime（ FSH）, and luteinizing hormone（LH） levels of the two group were significantly lower than before treatment（ P 〈 0.05 ）, and the estradiol, progesterone, FSH and LH levels of observation group were lower than the control group [ （ 1.08 ±0.32） nmoL/L vs （ 1.37 ± 0. 44 ） nmol/L, （42.68 ± 2. 94 ） pmol/L vs （56. 44±3.16） pmol/L,（12.24 ±3.56） U/L vs （15.43 ±3.86） U/L,（12.57 ±2.87） U/L vs （ 15.48 ± 3.54 ） U/L] （ P 〈 0.05 ）. The total effe
出处
《医学综述》
2016年第13期2646-2649,共4页
Medical Recapitulate
关键词
子宫肌瘤
米非司酮
宫瘤消胶囊
细胞因子
性激素
Uterine flbroids
Mifepristone
Uterine tumor eliminator capsule
Cytokine
Sex hormone
